Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
13.99 USD -1.41% Intraday chart for Alvotech -1.41% +21.86%
May. 24 Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating MT
May. 22 Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
Alvotech : Transactions of Managers and Closely Associated Persons
Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.
Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024
Alvotech Raises Revenue Guidance for the Full Year 2024
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket
Alvotech Narrows Q1 Loss as Revenue Increases
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
Alvotech Reports Earnings Results for the First Quarter Ended March 31, 2024
Alvotech Signs Commercialization Deal for Prolia, Xgeva Biosimilar
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab
Alvotech : and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Alvotech and Dr. Reddy's Enter into Collaboration for Commercialization of AVT03
The latest transactions by star managers
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S
Alvotech S.A. Annual General Meeting to be held June 7, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
  5. Other languages